Promising New Diabetes Treatment: Ecnoglutide

A new medication has emerged as a potential treatment for type 2 diabetes and weight management, positioning itself as a competitor to drugs like Ozempic. This drug, ecnoglutide, is a once-weekly injection that acts as a GLP-1 receptor agonist, akin to semaglutide (Ozempic) and dulaglutide (Trulicity), and appears to be effective in managing diabetes.

In a Phase 3 randomized controlled trial conducted by researchers at Fudan University and Hangzhou Sciwind Biosciences in China, ecnoglutide was found to be as effective as dulaglutide—commonly prescribed for diabetes—in lowering blood sugar levels. Interestingly, it may also aid in weight loss to a greater extent than dulaglutide, according to the researchers.

Diabetes affects over 38 million people in the U.S. (around 10% of the population), with approximately 90-95% of those cases being type 2. This condition occurs when the body struggles to utilize insulin effectively or doesn’t produce enough of it to manage blood sugar.

Both ecnoglutide and dulaglutide help control blood sugar levels by targeting the GLP-1 receptor in the body. Ecnoglutide specifically enhances insulin production and lowers blood sugar by focusing on certain pathways, avoiding others that could diminish the receptor’s function. In contrast, dulaglutide engages both pathways equally.

Feifei Jiang, one of the study authors, noted that “Ecnoglutide shows improved effectiveness in weight loss and blood sugar management compared to current medications.” In a year-long study involving over 600 adults with type 2 diabetes in China, those given ecnoglutide saw an average blood sugar decrease of about 1.9%, while those on dulaglutide experienced a reduction of 1.65%. Notably, ecnoglutide users also lost nearly double the weight—5.2% to 5.7%—compared to an average of 2.8% for dulaglutide users.

This additional weight loss could enhance diabetes management and lower the risk of heart disease, the study suggests. Jiang mentioned that side effects related to ecnoglutide are likely to mirror those experienced with similar GLP-1 receptor agonists, primarily gastrointestinal issues (like nausea and vomiting) and reduced appetite. Most difficulties reported were mild to moderate and tended to decrease over time with continued use.

Moreover, ecnoglutide is easier to produce than other GLP-1 receptor agonists. This could mean faster manufacturing times and lower costs compared to existing weight loss medications. Researchers see this as a promising indication that ecnoglutide could become an effective new option for managing type 2 diabetes while aiding weight loss.

The study also compared ecnoglutide to Ozempic, pointing out that “Ecnoglutide, a new GLP-1 receptor agonist, comprises entirely natural amino acids with modifications for enhanced stability and effectiveness, differing from semaglutide by just four amino acids.” These modifications improve both drug effectiveness and the manufacturing process. Unlike semaglutide, which requires complex chemical steps for production, ecnoglutide can be synthesized more straightforwardly through genetically engineered cells.

While this study provides insightful comparisons with dulaglutide, comparisons with semaglutide would be informative as well, particularly given their structural similarities and the greater effects seen with semaglutide. Yet, the researchers noted that limited access to semaglutide in China made direct comparisons impractical during the study period.

For now, the team suggests that looking at the Phase 3 SUSTAIN-China study of semaglutide might offer additional context. Even though no direct comparisons were made, the findings hint that their effectiveness may be similar. Future studies will need to establish direct comparisons.

According to Jiang, the SUSTAIN-China study indicated a blood sugar reduction of 1.4% to 1.7% with semaglutide after 30 weeks, while ecnoglutide users experienced a drop of 1.89% to 1.91% after 32 weeks. Weight loss mirrored that trend as well, with ecnoglutide participants losing 5.2% to 5.7% after 52 weeks compared to semaglutide’s 3.9% to 5.7% after 30 weeks.

These results suggest that ecnoglutide may be on par with or even outperform semaglutide in managing blood sugar levels. However, more research is needed to assess ecnoglutide’s effectiveness in diverse populations and alongside other diabetes medications.

Though ecnoglutide hasn’t yet received formal approval for marketing in any region, new drug applications are currently under review in China. Jiang added that combining ecnoglutide with lifestyle interventions—like dietary guidance and exercise—could enhance its effectiveness, helping patients build sustainable, healthy habits.